Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app objectively measure ADHD treatment success?

NCT ID NCT07217977

Knowledge-focused Sponsor: Qbtech AB Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a digital tool called QbMobile can accurately measure changes in ADHD symptoms after starting treatment. Researchers will enroll 175 people aged 6 to 60 who are newly diagnosed or not yet on medication. Participants use QbMobile to generate a symptom score, which is tracked over time to see if it reflects treatment effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide doctors with a more objective way to monitor ADHD treatment response, potentially improving care.
What could go wrong
This is an observational study, not a treatment trial. It only tests a monitoring tool, so it won't directly improve symptoms. Results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 175 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be selected from referrals or participating site's ADHD data base.

Ages

6 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile; * Aged \> 6 years and \< 60 years old; * Referred for an ADHD assessment or has a diagnosis of ADHD but not currently receiving any type of stimulant or nonstimulant medication treatment; * Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation) per sites standard clinical care evaluation; * Qbtech Rating Scale total score of \>24 at Visit 1; * Have adequate sensory and physical ability to complete QbMobile; * Possess or has access to an iPhone model that supports QbMobile. Exclusion Criteria: * Intellectual disability designated by IQ\<75); * Has used psychostimulant medication within 7 days prior to Visit 1; * A concurrent medical diagnosis that could significantly affect test performance (brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g., vascular dementia, Alzheimer disease, etc); * Other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain); * Substance use (e.g., alcohol, drugs) that may affect performance on the day of the test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention deficit disorder (ADD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention deficit disorder (ADD) Attention deficit disorder with hyperactivity (ADHD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    7 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bokhari Medical Consortium

    Largo, Florida, 33770, United States

  • CCM Clinical Research Group

    Miami, Florida, 33133, United States

  • Focus-MD

    Mobile, Alabama, 36607, United States

  • Godwin Psychiatry

    Goldsboro, North Carolina, 27534, United States

  • MindWell Urgent Care

    Dallas, Texas, 75247, United States

  • Nona Pediatric Center

    Orlando, Florida, 32829, United States

  • Prodigy Psychiatric Group

    San Jose, California, 95138, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.